Study Details

General Information

Roche Schizophrenia BP40283 Part B

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 in Patients with Schizophrenia or Schizoaffective Disorder and Negative Symptoms.

ProtocolBP40283 Part B
Identifier
UIDb36482a2-3fb2-4380-b731-58c6e59c2c2e
StatusDone - Archived
Phase2
CategorySchizophrenia / Adult
Launch Year2019
NCT Number-
Created2019-12-09 09:41
Last Updated2023-06-30 15:13

Description

No description provided.

Comment

CRI

Target Dates

NameDateRequired
Enrollment ClosedNo
Enrollment Open2019-12-16No
First Patient First VisitNo
Site Initiation Mtg.2018-11-06No
PI Meeting Start2018-10-17No
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout Date2023-05-17No
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalVolk, StephenSVolkNo
RecruiterGomez, KathieKGomezNo
CoordinatorMartinez, CassandraCMartinez1No
RegulatoryRamirez, ClaudiaCRamirezNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorRoche
DivisionRoche
TeamRoche
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB Ref
CROPPD Investigator Services, LLC
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?